Cardiovascular Diseases

Glucosamine Supplement Linked to Lower CVD Risk

A UK prospective cohort study suggested that habitual use of glucosamine supplement to relieve osteoarthritis pain might also be related to lower risks of cardiovascular diseases (CVD) events. The study enrolled 466 039 participants from 2006 to 2010. During a median follow-up of 7 years, there were 10 204 incident CVD events, 3060 CVD deaths, 5745 coronary heart disease events, and 3263 stroke events. After adjustment for age, sex, body mass index, race, lifestyle factors, dietary intakes, drug use, and other supplement use, glucosamine use was associated with a significantly lower risk of total CVD events (hazard ratio 0.85), CVD death (0.78), coronary heart disease (0.82), and stroke (0.91). The findings are in line with several previous studies and suggest that glucosamine might have a preventive role in CVD through anti-inflammatory and mimicking a low carbohydrate diet properties. Source: https://www.bmj.com/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

21 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

23 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.